Episode 48

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

  • Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)
  • Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)
  • Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37)

CME information and select publications

Next Episode All Episodes Previous Episode

About the Podcast

Show artwork for Lung Cancer Update
Lung Cancer Update
This series bridges the gap between research and patient care by providing medical oncologists and hematologists ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Listen for free